The CHMP recommended approval granting marketing authorization for Kisqali (ribociclib ... Novartis released new data from the ALITHIOS open-label extension study. Data show first-line Kesimpta ...

Continued expansion into new geographical markets and potential label extensions could further ... combined with existing treatments like ribociclib and fulvestrant. Success in this area could ...

Kisqali (ribociclib) given alongside endocrine therapy ... The drug made $2.5 billion in sales last year, and its label was extended in March to remove the need to test for the biomarker on ...

Get detailed information on Ribociclib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...

has adopted a positive opinion and recommended granting marketing authorization for Kisqali ® (ribociclib) for the adjuvant treatment of adults with hormone receptor-positive/human epidermal ...

The WHO’s guidance recommends governments implement “interpretive” labels that include nutritional information and some explanation of what that means about the healthiness of a product.

Similarly, in an open-label period of the study, proteinuria reduction was seen in participants who were switched to Fabhalta. In addition, improvement in estimated glomerular filtration rate ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

As the Lower House election approaches this Sunday, a barrage of articles profuse with political labels is appearing in the media. But none of the articles explain what the labels mean ...